Nasdaq:FATE

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day…

3 hours ago